- Trabectedin in Liposarcoma/Leiomyosarcoma🔍
- U.S. FDA Approves YONDELIS® 🔍
- Trabectedin Now FDA|Approved for Metastatic Soft Tissue Sarcomas🔍
- FDA Approves Trabectedin for Two Soft Tissue Sarcomas🔍
- FDA Approves Yondelis for Soft Tissue Sarcoma Subtypes🔍
- Search Orphan Drug Designations and Approvals🔍
- U.S. FDA Grants Priority Review for YONDELIS® 🔍
- Trabectedin🔍
FDA Approves Trabectedin for Sarcoma
Trabectedin in Liposarcoma/Leiomyosarcoma: The Drug Is ...
Based in large part upon [the phase III trial of trabectedin], the FDA made the right decision to approve this drug. —Laurence H. Baker, DO.
U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of ...
today announced the U.S. Food and Drug Administration (FDA) has approved YONDELIS® (trabectedin) for the treatment of patients with unresectable ...
Trabectedin Now FDA-Approved for Metastatic Soft Tissue Sarcomas
Trabectedin (Yondelis) chemotherapy was approved by the FDA for treatment of patients with specific metastatic soft tissue ...
FDA Approves Trabectedin for Two Soft Tissue Sarcomas - Medscape
FDA Approves Trabectedin for Two Soft Tissue Sarcomas ... The US Food and Drug Administration (FDA) has approved the chemotherapy trabectedin ( ...
FDA Approves Yondelis for Soft Tissue Sarcoma Subtypes
The U.S. Food and Drug Administration has approved Yondelis (trabectedin) for the treatment of patients with the soft tissue sarcomas ...
Search Orphan Drug Designations and Approvals - FDA
Marketing approved: ; 1 ; trabectedin · Yondelis · 10/23/2015 · For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who ...
U.S. FDA Grants Priority Review for YONDELIS® (trabectedin) for ...
RARITAN, NJ, February 3, 2015 · About Soft Tissue Sarcoma · About YONDELIS® (trabectedin) · About Janssen Research & Development, LLC · Janssen in ...
Yondelis. FDA Approved. Yes. FDA label information for this drug is available at DailyMed. Use in Cancer. Trabectedin is approved to treat:.
Clinical Review Amy Barone, MD NDA 207953 S004 YONDELIS ...
... approved treatment for relapsed or refractory bone or soft tissue sarcoma ... • October 23, 2015: The FDA approved JRD's NDA 207953 for ...
FDA Approves Trabectedin for Metastatic or Unresectable Soft ...
The FDA has approved trabectedin (Yondelis) for treatment of unresectable or metastatic soft tissue sarcoma.
FDA Approves Trabectedin for Liposarcoma, Leiomyosarcoma
Treatment shows significant improvement in progression-free survival in patients with unresectable or metastatic liposarcoma or leiomyosarcoma.
The European Commission and the U.S. Food and Drug Administration (FDA) granted orphan drug status to trabectedin for soft-tissue sarcomas and ovarian cancer.
FDA approves Yondelis for liposarcoma and leiomyosarcoma
The FDA has approved Yondelis for the treatment of specific soft tissue sarcomas– liposarcoma and leiomyosarcoma – that is unresectable or ...
New treatment option approved for soft-tissue sarcoma - CareAcross
The FDA has approved trabectedin (Yondelis) for certain types of unresectable or metastatic soft-tissue sarcomas (STS) previously treated ...
3837231 This label may not be the latest approved by FDA. For ...
Other clinically important adverse reactions observed in <10% of patients (N=755) with soft tissue sarcoma receiving YONDELIS were: Nervous system disorders ...
FDA Approves J&J's Cancer Drug Yondelis - Bloomberg Law News
The FDA Oct. 23 approved Yondelis (trabectedin), a chemotherapy for treating patients with specific soft tissue sarcomas, ...
Soft Tissue Sarcoma Update, Issue 1, 2017 (Video Program)
And I think because there was so much uproar in the sarcoma community because trabectedin hadn't been approved, I think the FDA took a closer look at approving ...
FDA Approves Trabectedin for Unresectable or Advanced ...
The FDA approved trabectedin (Yondelis) for the treatment of unresectable or metastatic liposarcoma and leiomyosarcoma.
Trabectedin: Uses, Interactions, Mechanism of Action - DrugBank
On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas. Type: Small Molecule ...
Use of Trabectedin in Soft Tissue Sarcoma - OncLive
The drug has now been, finally, filed with the FDA in November 2014 based on the results of a randomized phase III trial in patients with ...